Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more
Sinphar Pharmaceutical Co Ltd (1734) - Total Assets
Latest total assets as of September 2025: NT$6.13 Billion TWD
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) holds total assets worth NT$6.13 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinphar Pharmaceutical Co Ltd - Total Assets Trend (2002–2024)
This chart illustrates how Sinphar Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sinphar Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinphar Pharmaceutical Co Ltd's total assets of NT$6.13 Billion consist of 41.7% current assets and 58.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.1% |
| Accounts Receivable | NT$641.90 Million | 10.2% |
| Inventory | NT$714.91 Million | 11.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$72.16 Million | 1.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinphar Pharmaceutical Co Ltd's current assets represent 41.7% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2024, up from 6.1% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 11.4% of total assets.
Sinphar Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Sinphar Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sinphar Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Sinphar Pharmaceutical Co Ltd generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sinphar Pharmaceutical Co Ltd generates $ 4.84 in net profit.
Sinphar Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.27 | 1.91 |
| Quick Ratio | 1.56 | 1.58 | 1.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.39 Billion | NT$ 1.45 Billion | NT$ 1.21 Billion |
Sinphar Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sinphar Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | NT$6.30 Billion |
| Market Capitalization | $129.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinphar Pharmaceutical Co Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sinphar Pharmaceutical Co Ltd's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sinphar Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual total assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$6.30 Billion | +0.75% |
| 2023-12-31 | NT$6.25 Billion | +1.07% |
| 2022-12-31 | NT$6.19 Billion | -0.57% |
| 2021-12-31 | NT$6.22 Billion | +1.53% |
| 2020-12-31 | NT$6.13 Billion | +3.56% |
| 2019-12-31 | NT$5.92 Billion | +0.65% |
| 2018-12-31 | NT$5.88 Billion | -2.73% |
| 2017-12-31 | NT$6.04 Billion | -2.63% |
| 2016-12-31 | NT$6.21 Billion | -2.82% |
| 2015-12-31 | NT$6.39 Billion | -1.20% |
| 2014-12-31 | NT$6.46 Billion | +13.33% |
| 2013-12-31 | NT$5.70 Billion | +25.74% |
| 2012-12-31 | NT$4.54 Billion | -2.22% |
| 2011-12-31 | NT$4.64 Billion | +24.92% |
| 2010-12-31 | NT$3.71 Billion | +3.60% |
| 2009-12-31 | NT$3.58 Billion | -0.25% |
| 2008-12-31 | NT$3.59 Billion | +13.54% |
| 2007-12-31 | NT$3.16 Billion | +14.05% |
| 2006-12-31 | NT$2.77 Billion | -2.26% |
| 2005-12-31 | NT$2.84 Billion | +20.99% |
| 2004-12-31 | NT$2.35 Billion | +13.88% |
| 2003-12-31 | NT$2.06 Billion | +24.74% |
| 2002-12-31 | NT$1.65 Billion | -- |